Loss of p16INK4A protein expression as a result of homozygous loss of the CDKN2A genomic region has previously been shown to correlate with poor prognosis as well as a poor response to neoadjuvant chemotherapy in osteosarcoma patients13–18,25,38. Here, CDKN2A is linked to osteosarcoma.